lung cancer non-small cell lung carcinom
Conditions
Interventions
Radiotherapy with integrated boost on primary tumor on the basis of a
pre-treatment FDG-PET-CT scan
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients > 18 years with any subtype of pathologically proven, non-small cell lung cancer. The diagnosis may be established from biopsy or cytology obtained from the primary tumor and/ or from metastatic lymph nodes. 2. Minimal diameter of the primary tumor 4 cm, to allow boosting of sub-volumes. 3. UICC Stage T2-4, N0-3, M0 disease (TNM definition see appendix 2). 4. Only stage IB-II patients who are not candidates for surgery are eligible 5 Measurable disease at registration. 6. ECOG-performance status
Exclusion criteria
Exclusion criteria: 1. Prior radiotherapy to the thorax. 2. Clinical superior vena cava syndrome, malignant pleural effusion or malignant pericardial effusion. 3. Tumor growth in large blood vessels on spiral CT scan or encasement >50 % 4. Multiple nodules in the same or ipsilateral lobe(s). 5. Post-obstructive atelectasis or infiltration that cannot be distinguished from tumor on a CT-PET scan. 6. Patients with a diagnosis of other cancer within the last 3-years (except in situ carcinoma*s and / or non-melanoma skin cancer). 7. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Freedom from local failure in patients alive at 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity Overall survival Quality of life Distant metastases Local and regional failures outside PTV Correlation between intra-tumor recurrence 3 and 12 months post radiotherapy based on average PET CT , 18F HX4 and DCE-CT scan Correlation between intra-tumor recurrence 3 and 12 months post radiotherapy based on average PET CT and 18F HX4. Correlation between distant metastases and 18F HX4 uptake in the primary tumor. | — |
Countries
Netherlands
Outcome results
None listed